AFT Pharmaceuticals Limited — Director's Dealing 2018

Dec 14, 2018

==> picture [119 x 28] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited; and
Name of listed issuer:		AFT PharmaceuticalsLimited (AFT)
Date this disclosure made:		13-Dec-18
Date of last disclosure:		22-Aug-18
Director or senior manager giving disclosure
Full name(s):		DavidFlacks
Name of listed issuer:		AFT PharmaceuticalsLimited (AFT)
Name of related body corporate (if applicable):		Not applicable
Position held in listed issuer:		Director
Summary of acquisition or disposal of relevant interest(excluding specified derivatives)
Class of affected quoted financial products:		Fully-Paid Ordinary Sharesin AFT
Nature of the affected relevant interest(s):		Joint registered holder and beneficial owner of ordinary shares
**For that relevant interest- **
Number held in class before acquisition or disposal:		115,431
Number held in class after acquisition or disposal:		145,431
Current registered holder(s):		Unknown
Registered holder(s) once transfers are registered:		David Mark Flacks & Adina Rita Betty Halpern as trustees of WaitemataFamilyTrust
Details of transactions giving rise to acquisition or disposal
Total numberoftransactions towhich noticerelates:		1
Details of transactions requiring disclosure-
Date oftransaction:		12-Dec-18
Nature oftransaction:		On-market acquisitionofordinary shares
Name ofany otherparty orparties to the transaction(if known)		Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:		NZ$2.1967pershare / $65,901.00
Numberof financialproducts towhichthe transaction related:		30,000
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevantinterestswere acquired ordisposed ofduring a closed period		No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:		Not applicable
Date of the prior written clearance (if any):		Not applicable
Summary of other relevant interests after acquisition or disposal: Class ofquotedfinancialproducts: Nature of relevantinterest: For that relevant interest,- Number heldinclass: Currentregisteredholder(s): For a derivative relevant interest,- Type ofderivative: Details of derivative,-
		Not applicable
		Not applicable
		Not applicable
		Not applicable
		Not applicable
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):		Not applicable
A statement as to whether the derivative is cash settled or physically settled		Not applicable
Maturity date of the derivative (if any):		Not applicable
Expiry date of the derivative (if any):		Not applicable
The price's specified terms (if any):		Not applicable
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:		Not applicable
For that derivative relevant interest,-
Parties to the derivative:		Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		Not applicable
Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer: Date of signature:
		13-Dec-18

David Flacks AFT Pharmaceuticals Limited (AFT) Not applicable Director Fully-Paid Ordinary Shares in AFT Joint registered holder and beneficial owner of ordinary shares 115,431 145,431 Unknown David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust